| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Magdalena Świądro-Piętoń, Dominika Dudek, Renata Wietecha-Posłuszn. Direct Immersion-Solid Phase Microextraction for Therapeutic Drug Monitoring of Patients with Mood Disorders. Molecules (Basel, Switzerland). vol 29. issue 3. 2024-02-10. PMID:38338419. |
it has been adapted to identify the most commonly used drugs in mood disorders, including amitriptyline, citalopram, fluoxetine, paroxetine, sertraline, trazodone, duloxetine, venlafaxine, lamotrigine, quetiapine, olanzapine, and mirtazapine. |
2024-02-10 |
2024-02-12 |
Not clear |
| Mohammad Sayadnasiri, Sahar Darvishskandari, Maryam Latifian, Sheikh Mohammed Shariful Isla. The Effect of Adding Mirtazapine to Quetiapine on Reducing Agitation in Patients with Alzheimer's Disease. Journal of Alzheimer's disease reports. vol 8. issue 1. 2024-02-05. PMID:38312532. |
the effect of adding mirtazapine to quetiapine on reducing agitation in patients with alzheimer's disease. |
2024-02-05 |
2024-02-07 |
Not clear |
| Ana Salomé Correia, Lara Marques, Armando Cardoso, Nuno Val. Exploring the Role of Drug Repurposing in Bridging the Hypoxia-Depression Connection. Membranes. vol 13. issue 9. 2023-09-27. PMID:37755222. |
by the induction of hypoxia in sh-sy5y cells through a hypoxia incubator chamber or cobalt chloride treatment, the effect of mirtazapine, an antidepressant, and other drugs that interact with serotonin receptors (tcb-2, dextromethorphan, ketamine, quetiapine, scopolamine, celecoxib, and lamotrigine) on sh-sy5y cellular viability and morphology was explored. |
2023-09-27 |
2023-10-07 |
Not clear |
| Gudrun Hefner, Jan Wolff, Sermin Toto, Pamela Reißner, Ansgar Klimk. Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry. Journal of neural transmission (Vienna, Austria : 1996). 2022-09-07. PMID:36070009. |
the most often off-label prescribed drugs were quetiapine and mirtazapine for organic mental disorders (f0/g3), valproate and quetiapine in patients with disorders due to psychoactive substance use (f1), valproate in patients with psychotic disorders (f2), and risperidone and olanzapine in patients with affective disorders (f3). |
2022-09-07 |
2023-08-14 |
Not clear |
| Håvard Breivik, Trine N Løkken, Lars Slørdal, Joachim Fros. A Validated Method for the Simultaneous Determination of Quetiapine, Clozapine and Mirtazapine in Postmortem Blood and Tissue Samples. Journal of analytical toxicology. vol 44. issue 5. 2020-08-13. PMID:32020166. |
within-run and between-run accuracy (87.4-122%) and precision (cv 1.5-8.9%), matrix effects (95-101%) and recovery (35.7-92%) were validated at two concentration levels; 5.8 and 1227 μg/l for quetiapine, 25 and 1568 μg/l for clozapine and 20 and 849 μg/l for mirtazapine. |
2020-08-13 |
2023-08-13 |
Not clear |
| Emeric Saguin, S Keou, C Ratnam, C Mennessier, H Delacour, B Lahutt. Severe rhabdomyolysis induced by quetiapine and mirtazapine in a French military soldier. Journal of the Royal Army Medical Corps. vol 164. issue 2. 2018-07-24. PMID:29632134. |
it is our opinion that 5-hydroxytryptamine 2a serotonergic receptors inhibition (related to mirtazapine and quetiapine) associated with muscle training was responsible for inducing rhabdomyolysis. |
2018-07-24 |
2023-08-13 |
Not clear |
| Mary F Brunette, Sarah C Akerman, Ree Dawson, Christopher D O'Keefe, Alan I Gree. An open-label pilot study of quetiapine plus mirtazapine for heavy drinkers with alcohol use disorder. Alcohol (Fayetteville, N.Y.). vol 53. 2018-01-03. PMID:27256763. |
in an open-label pilot study of subjects with alcohol dependence, we tested whether the combination of quetiapine, a weak dopamine d2 receptor antagonist, whose primary metabolite, desalkylquetiapine, is a norepinephrine reuptake inhibitor, and mirtazapine, a potent α2 norepinephrine receptor antagonist, would decrease alcohol drinking and craving. |
2018-01-03 |
2023-08-13 |
human |
| Germán Gaete, Álvaro Velásque. [Ictal catatonia presentation as a non-convulsive status epilepticus: A case report]. Revista medica de Chile. vol 145. issue 1. 2017-08-04. PMID:28393979. |
we report a 68 years old male with a history of depression treated with venlafaxine, mirtazapine, quetiapine and risperidone, presenting in the emergency room with confusion and generalized rigidity. |
2017-08-04 |
2023-08-13 |
Not clear |
| Brian D Poeschla, Pauline Bartle, Karen P Hanse. Serotonin syndrome associated with polypharmacy in the elderly. General hospital psychiatry. vol 33. issue 3. 2011-09-29. PMID:21601732. |
we describe a case of serotonin syndrome in a 79-year-old man taking mirtazapine, venlafaxine and quetiapine. |
2011-09-29 |
2023-08-12 |
Not clear |
| Gabriele Mas. Pharmacotherapy of pervasive developmental disorders in children and adolescents. CNS drugs. vol 18. issue 14. 2004-12-29. PMID:15584771. |
pharmacological, efficacy and safety data on drugs acting on serotonin (serotonergic agents such as clomipramine, fluoxetine, paroxetine, sertraline, citalopram and fluvoxamine), on both serotonin and norepinephrine (venlafaxine and mirtazapine), dopamine (dopamine-blocking antipsychotics such as haloperidol and pimozide), and on both serotonin and dopamine (atypical antipsychotics such as clozapine, risperidone, olanzapine, quetiapine and ziprasidone) are presented. |
2004-12-29 |
2023-08-12 |
Not clear |